Insulin Resistance and Weight Loss in Obese Women with Polycystic Ovary Syndrome Treated with Liraglutide—Single Institution Experience
Abstract
Background: Insulin resistance contributes to the pathogenesis of polycystic ovary syndrome (PCOS) in obese women, but its predictive value for weight loss with liraglutide treatment is unknown. Methods: Retrospective cohort study of 16 obese (BMI ≥30 kg/m 2 ), nondiabetic women aged 18-42 with PCOS who were seen in a weight loss clinic between November 2014 and November 2016 and prescribed liraglutide (either 1.8 mg/day or 3.0 mg/day based on insurance coverage) and metformin. Maximum weight loss achieved from baseline until 2 to 13 months post-liraglutide initiation was compared. Spearman’s rank correlation was used to establish the relationship between pre-treatment Homeostatic Model for Insulin Resistance (HOMA-IR) and % weight loss. The University of Pennsylvania Institutional Review Board approved the study. Results: Overall median weight loss was 4.4 kg (-3.4% of initial weight). Median weight loss was -4.7 kg (-3.7%) in women treated with 3.0 mg daily (n=6) and -2.5 kg (-2.0%) in women treated with 1.8 mg (n=10). 6/16 (37.5%) of women experienced >5% weight loss: 2/6 women treated with 3.0 mg daily dosing, and 4/10 women treated with 1.8 mg daily. HOMA-IR at baseline was not associated strongly with % weight loss achieved for all subjects (r s = -0.31, p=0.24), or when stratified to examine those subjects receiving 3.0 mg daily (r s = -0.20; p=0.70) or 1.8 mg daily (r s = -0.36, p=0.31). Conclusions: In this small study, our findings suggest that insulin resistance…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.